Rachel Ann Freedman MD MPH

Breast Cancer

Associate Professor of Medicine, Harvard Medical School; Medical Oncologist, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute; Clinical Researcher

Join to view full profile

450 Brookline AveBoston, MA 02215
Phone+1 617-632-3800

Dr. Freedman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Freedman's full profile Already have an account?

Summary

Dr. Rachel Freedman is an oncology specialist based in Boston, MA, with a focus on breast cancer. She completed her residency at Beth Israel Deaconess Medical Center and her fellowship at Mass General Brigham institutions. She holds an MPH in Clinical Effectiveness from Harvard School of Public Health. Dr. Freedman is an Associate Professor at Medicine at Harvard Medical School and an Institute Physician at Dana-Farber Cancer Institute. She has a breadth of experience in breast cancer, hereditary cancers, geriatrics, healthcare disparities, and health services accessibility. Her recent publications have appeared in high-impact journals such as Nature Aging and Cancer, and she is involved in conducting clinical trials focused on breast cancer in older adults. She is also the Director for the Center for Cancer and Aging at Dana-Farber.

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2009
Harvard T.H. Chan School of Public HealthMPH, Clinical Effectiveness, 2007 - 2008
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2003 - 2006
Georgetown University School of MedicineClass of 2003

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
RI State Medical License 2022 - 2028
ME State Medical License 2022 - 2027
NH State Medical License 2023 - 2027
CT State Medical License 2022 - 2026
MA State Medical License 2005 - 2026
OH State Medical License 2022 - 2026
VT State Medical License 2022 - 2026
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017

Clinical Trials

The Hurria Older PatiEnts (HOPE) With Breast Cancer Study Start of enrollment: 2011 Sep 09
ACTIVE_NOT_RECRUITING
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
COMPLETED
PHASE2
Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Start of enrollment: 2012 Dec 11
COMPLETED
PHASE2

Publications & Presentations

PubMed

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases.
Thomas Grinda, Hillary M Heiling, Nabihah Tayob, Karen L Smith, Raechel Davis
Breast. 2026-07-20
Research Letter: Frailty Within a Cohort of Older Adults With Breast Cancer: Groundwork for Future Geriatric-Specific Outcomes Data.
Christina A Minami, Hillary M Heiling, Nabihah Tayob, Melissa E Hughes, Craig Snow
Journal of the American Geriatrics Society. 2026-06-03
Digitally engaging participants in cancer clinical trials: Design and pilot of the Alliance Participant Engagement Portal (PEP).
Norah L Crossnohere, Nancy Campbell, Electra D Paskett, Marie E Wood, Rachel A Freedman
JNCI Cancer Spectrum. 2026-05-09

Journal Articles

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Press Mentions

Oncologists Face Unique Challenges with Older Cancer PatientsSeptember 2nd, 2025
Rachel Freedman on Adjuvant CDK4/6 Therapy for Early Breast CancerNovember 19th, 2024
‘Real Housewives of Miami’ Star Guerdy Abraira Reveals Breast Cancer DiagnosisMay 10th, 2023

Grant Support

Individualizing Approaches to Surveillance Mammography in Older Breast Cancer SurvivorsDANA-FARBER CANCER INST2024–2029
Individualizing Approaches to Surveillance Mammography in Older Breast Cancer SurvivorsDANA-FARBER CANCER INST2024–2029